Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

SIMPLE SUMMARY: Clinical trials for new drugs to treat rare diseases are difficult to evaluate due to the limited patient population available for recruitment. Growth modulation index (GMI) is a very useful tool in these instances, as this calculation compares the patient’s outcome on the current dr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancers (Basel)
Autori principali: Italiano, Antoine, Nanda, Shivani, Briggs, Andrew, Garcia-Foncillas, Jesus, Lassen, Ulrik, Vassal, Gilles, Kummar, Shivaani, van Tilburg, Cornelis M., Hong, David S., Laetsch, Theodore W., Keating, Karen, Reeves, John A., Fellous, Marc, Childs, Barrett H., Drilon, Alexander, Hyman, David M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7692104/
https://ncbi.nlm.nih.gov/pubmed/33158040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113246
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi